Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01300793 · ClinicalTrials.gov registry record · Phase 1
Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide
A Phase 1 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01300793 is a Phase 1 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 6 participants.
The verdict
NCT01300793, a Phase 1 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Primary objective of the study is to determine the maximum tolerated dose (MTD) of bortezomib (Velcade) in combination with rituximab, ifosfamide, carboplatin and etoposide for adult patients with relapsed or refractory aggressive B-cell lymphoma. The secondary objectives are to assess the tolerability and safety, the response rate, rate of autologous stem cell transplant and CD34+ progenitor cell collection and engraftment after treatment with this regimen.
Interventions
- DRUG Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-05 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01300793
The ClinicalTrials.gov registry entry for NCT01300793 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide is the first listed.
NCT01300793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01300793 about?
NCT01300793 is a clinical study titled "Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide". Primary objective of the study is to determine the maximum tolerated dose (MTD) of bortezomib (Velcade) in combination with rituximab, ifosfamide, carboplatin and etoposide for adult patients with relapsed or refractory aggressive B-cell lymphoma. The secondary objectives are to assess the tolerabil...
What is the current status of trial NCT01300793?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2007-05. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01300793?
The interventions under investigation include: Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide (DRUG).
Who is sponsoring clinical trial NCT01300793?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.